↓ Skip to main content

Virus vector-mediated genetic modification of brain tumor stromal cells after intravenous delivery

Overview of attention for article published in Journal of Neuro-Oncology, May 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (87th percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news
1 news outlet
blogs
1 blog
twitter
4 X users

Citations

dimensions_citation
24 Dimensions

Readers on

mendeley
64 Mendeley
Title
Virus vector-mediated genetic modification of brain tumor stromal cells after intravenous delivery
Published in
Journal of Neuro-Oncology, May 2018
DOI 10.1007/s11060-018-2889-2
Pubmed ID
Authors

Adrienn Volak, Stanley G. LeRoy, Jeya Shree Natasan, David J. Park, Pike See Cheah, Andreas Maus, Zachary Fitzpatrick, Eloise Hudry, Kelsey Pinkham, Sheetal Gandhi, Bradley T. Hyman, Dakai Mu, Dwijit GuhaSarkar, Anat O. Stemmer-Rachamimov, Miguel Sena-Esteves, Christian E. Badr, Casey A. Maguire

Abstract

The malignant primary brain tumor, glioblastoma (GBM) is generally incurable. New approaches are desperately needed. Adeno-associated virus (AAV) vector-mediated delivery of anti-tumor transgenes is a promising strategy, however direct injection leads to focal transgene spread in tumor and rapid tumor division dilutes out the extra-chromosomal AAV genome, limiting duration of transgene expression. Intravenous (IV) injection gives widespread distribution of AAV in normal brain, however poor transgene expression in tumor, and high expression in non-target cells which may lead to ineffective therapy and high toxicity, respectively. Delivery of transgenes encoding secreted, anti-tumor proteins to tumor stromal cells may provide a more stable and localized reservoir of therapy as they are more differentiated than fast-dividing tumor cells. Reactive astrocytes and tumor-associated macrophage/microglia (TAMs) are stromal cells that comprise a large portion of the tumor mass and are associated with tumorigenesis. In mouse models of GBM, we used IV delivery of exosome-associated AAV vectors driving green fluorescent protein expression by specific promoters (NF-κB-responsive promoter and a truncated glial fibrillary acidic protein promoter), to obtain targeted transduction of TAMs and reactive astrocytes, respectively, while avoiding transgene expression in the periphery. We used our approach to express the potent, yet toxic anti-tumor cytokine, interferon beta, in tumor stroma of a mouse model of GBM, and achieved a modest, yet significant enhancement in survival compared to controls. Noninvasive genetic modification of tumor microenvironment represents a promising approach for therapy against cancers. Additionally, the vectors described here may facilitate basic research in the study of tumor stromal cells in situ.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 64 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 64 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 12 19%
Researcher 11 17%
Student > Bachelor 9 14%
Student > Master 3 5%
Professor 3 5%
Other 4 6%
Unknown 22 34%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 14 22%
Medicine and Dentistry 8 13%
Neuroscience 8 13%
Agricultural and Biological Sciences 3 5%
Pharmacology, Toxicology and Pharmaceutical Science 2 3%
Other 6 9%
Unknown 23 36%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 March 2019.
All research outputs
#1,806,562
of 23,056,273 outputs
Outputs from Journal of Neuro-Oncology
#94
of 2,989 outputs
Outputs of similar age
#41,067
of 327,735 outputs
Outputs of similar age from Journal of Neuro-Oncology
#4
of 87 outputs
Altmetric has tracked 23,056,273 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,989 research outputs from this source. They receive a mean Attention Score of 4.2. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 327,735 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 87 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.